Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29640806 | 1.00 | HDAC1 (0.45) | HDAC1HDAC6P2RX7ADORA2ACXCR4 | |
| SCHEMBL11983384 | 0.90 | FNTA (0.40) | HDAC1HDAC6P2RX7FNTAFNTB | |
| SCHEMBL2597816 | 0.86 | HDAC1 (0.46) | HDAC1HDAC6P2RX7ADORA2ACXCR4 | |
| SCHEMBL27766407 | 0.85 | HDAC1 (0.44) | HDAC1HDAC6P2RX7ADORA2ACXCR4 | |
| SCHEMBL2305432 | 0.84 | HDAC1 (0.45) | HDAC1HDAC6P2RX7ADORA2ACXCR4 | |
| SCHEMBL27951689 | 0.84 | HDAC1 (0.46) | HDAC1HDAC6P2RX7ADORA2ACXCR4 | |
| SCHEMBL3312236 | 0.84 | HDAC1 (0.46) | HDAC1HDAC6P2RX7ADORA2ACXCR4 | |
| SCHEMBL30558705 | 0.84 | HDAC1 (0.46) | HDAC1HDAC6P2RX7ADORA2ACXCR4 | |
| SCHEMBL9770662 | 0.82 | MCL1 (0.49) | HDAC1HDAC6P2RX7CXCR4F2 | |
| SCHEMBL12185906 | 0.80 | HDAC1 (0.43) | HDAC1HDAC6CXCR4FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405453-B1 | A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND | PTT GLOBAL CHEMICAL PUBLIC CO LTD (TH) | 2024-05-29 | — | — | EP | claimed |
| US-10759904-B2 | Method for preparing poly(carbonate-etherimide) compound | PTT GLOBAL CHEMICAL PUBLIC COMPANY LIMITED (TH) | 2020-09-01 | — | — | US | claimed |
| US-20190202980-A1 | METHOD FOR PREPARING POLY(CARBONATE-ETHERIMIDE) COMPOUND | PTT GLOBAL CHEMICAL PUBLIC COMPANY LIMITED (TH) | 2019-07-04 | — | — | US | claimed |
| EP-3405453-A2 | A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND | PTT Global Chemical Public Company Limited (TH) | 2018-11-28 | — | — | EP | claimed |
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3405453-B1 | A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND | PTT GLOBAL CHEMICAL PUBLIC CO LTD (TH) | 2024-05-29 | — | — | EP | disclosed |
| US-20220331304-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. | 2022-10-20 | — | — | US | disclosed |
| WO-2022091001-A1 | PROCESS FOR PREPARATION OF PALBOCICLIB | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-05-05 | — | — | WO | disclosed |
| CN-109071488-B | Substituted 1,2, 3-triazoles as NR 2B-selective NMDA modulators | 詹森药业有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-20210115008-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. | 2021-04-22 | — | — | US | disclosed |
| EP-3752497-A1 | P300/CBP HAT INHIBITORS | Constellation Pharmaceuticals, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20130196985-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzzhou Institute of Biomedicine and Health, Chineses Academy of Sciences (CN) | 2013-08-01 | — | — | US | disclosed |
| EP-2594567-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences (CN) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109566-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2013062981-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012061290-A2 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120110702-A1 | Pesticidal Compositions and Processes Related Thereto | CORTEVA AGRISCIENCE LLC | 2012-05-03 | — | — | US | disclosed |
| CN-101402537-B | Uses of 2-pyridine-beta ketone compounds | GUANGZHOU INST BIOMED & HEALTH | 2011-04-27 | — | — | CN | disclosed |
| CN-101402537-A | Uses of 2-pyridine-beta ketone compounds | GUANGZHOU INST BIOMED & HEALTH (CN) | 2009-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109566-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | ACHE, DDT, PTMS | HDAC1 2725/4885HDAC6 1719/4885P2RX7 181/4885 |
| US-20210115008-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | HDAC1 2/4885HDAC6 28/4885P2RX7 4072/4885 |
| US-20130196985-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | ABCB1, VHL, ABCC1 | HDAC1 2883/4885HDAC6 1926/4885P2RX7 478/4885 |
| US-20220331304-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CLN6, ACHE, NLN | HDAC1 1289/4885HDAC6 112/4885P2RX7 1343/4885 |
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | HDAC1 2/4885HDAC6 28/4885P2RX7 4072/4885 |
| US-20120110702-A1 | Pesticidal Compositions and Processes Related Thereto | ACHE, DDT, PTMS | HDAC1 2725/4885HDAC6 1719/4885P2RX7 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.